Homeostasis

Statera Biopharma, Inc. to Participate in the Cantor Virtual Global Healthcare Conference

Tuesday, September 21, 2021 - 12:31pm

FORT COLLINS, Colo., Sept. 21, 2021 /PRNewswire/ -- Statera Biopharma, Inc. (Nasdaq: STAB), a leading biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, will participate in the 2021 Cantor Virtual Global Healthcare Conference taking place September 27-30, 2001. Michael K. Handley, President and Chief Executive Officer of Statera, will participate in a virtual fireside chat on Thursday, September 30, 2021.

Key Points: 
  • A webcast of the discussion will be available on the Investor Relations section of the Statera website following the conference.
  • Investors who wish to register for the conference should contact their Cantor Fitzgerald sales representative.
  • The company announced its new corporate name, Statera BioPharma, on August 31, 2021.
  • Statera has clinicalprograms for Crohn's disease (STAT-201),hematology (Entolimod), pancreatic cancer (STAT-401) andCOVID-19 (STAT-205) in addition to expansion into fibromyalgia and multiple sclerosis.To learn more about Statera Biopharma, please visit www.staterabiopharma.com .

Hua and Sinopharm Announced Supply Chain Strategic Cooperation

Wednesday, September 15, 2021 - 6:35am

SHANGHAI, CHINA, Sept 15, 2021 - (ACN Newswire) - On September 13, 2021, Hua Medicine (Shanghai) Ltd. (the "Hua Medicine", Stock Code: 2552.HK) has signed a supply chain strategic cooperation agreement with Sinopharm Group Co., Ltd. (the "Sinopharm", Stock Code: 1099).

Key Points: 
  • SHANGHAI, CHINA, Sept 15, 2021 - (ACN Newswire) - On September 13, 2021, Hua Medicine (Shanghai) Ltd. (the "Hua Medicine", Stock Code: 2552.HK) has signed a supply chain strategic cooperation agreement with Sinopharm Group Co., Ltd. (the "Sinopharm", Stock Code: 1099).
  • Hua Medicine will rely on Sinopharm's nation-wide drug distribution network to carry out in-depth cooperation in supply chain management.
  • "We are very glad to witness the strategic cooperation between Sinopharm and Hua Medicine, opening a new chapter on our cooperation.
  • In recent years, Sinopharm continue to innovate and build up the new ecosystem of the smart pharmaceutical and supply chain, improving the efficiency of supply chain.

Eliem Therapeutics Reports Second Quarter Financial Results

Monday, September 13, 2021 - 9:10pm

SEATTLE and CAMBRIDGE, United Kingdom, Sept. 13, 2021 (GLOBE NEWSWIRE) -- Eliem Therapeutics, Inc., a clinical-stage biotechnology company focused on developing novel therapies for neuronal excitability disorders to address unmet needs in chronic pain, psychiatry, epilepsy and other disorders of the peripheral and central nervous systems, today reported financial results and business highlights for the quarter ended June 30, 2021.

Key Points: 
  • In the second quarter, we continued to advance enrollment on our two Phase 2a studies for ETX-810 in patients with chronic pain conditions.
  • The IPO was preceded by a Series B financing in May 2021 that raised gross proceeds of $60.0 million.
  • At its core, the Eliem team is motivated by the promise of helping patients live happier, more fulfilling lives.
  • Additional information will also be set forth in Eliem's other reports and filings it will make with the SEC from time to time.

Enzychem Lifesciences Announces Database Lock for Phase 2 Study of EC-18 in Chemoradiation-Induced Oral Mucositis

Monday, September 13, 2021 - 6:00pm

Enzychem Lifesciences (KOSDAQ: 183490), announced today database lock for the Phase 2 clinical trial of its lead program EC-18 in chemoradiation-induced oral mucositis (CRIOM) had been completed last August.

Key Points: 
  • Enzychem Lifesciences (KOSDAQ: 183490), announced today database lock for the Phase 2 clinical trial of its lead program EC-18 in chemoradiation-induced oral mucositis (CRIOM) had been completed last August.
  • EC-18, the companys lead investigational candidate, is a novel, first-in-class, oral immunomodulator, which facilitates rapid resolution of inflammation and early return to homeostasis.
  • EC-18 has a unique mechanism of action which prevents excessive neutrophil recruitment to the inflamed sites and, thereby, lessens the severity of oral mucositis.
  • Founded in 1999, the company's lead compound, EC-18 is in clinical development in Phase 2 clinical trials in chemoradiation-induced oral mucositis and COVID-19.

Vitalgenics Inc Has Unraveled the Mystery of Pancreatic Ductal Adenocarcinoma (PDAC).

Thursday, September 9, 2021 - 1:01pm

Vitalgenics Inc, a clinical stage biopharmaceutical company specializing in pancreatic cancer, has unraveled the etiology of pancreatic ductal adenocarcinoma (PDAC) with their FDA repurposed immunotherapy drug called Excindogen.

Key Points: 
  • Vitalgenics Inc, a clinical stage biopharmaceutical company specializing in pancreatic cancer, has unraveled the etiology of pancreatic ductal adenocarcinoma (PDAC) with their FDA repurposed immunotherapy drug called Excindogen.
  • 95% of all pancreatic cancers are PDAC with a 7%- 9% survival rate after 5 years.
  • PDAC consist of 40 continuous biological sequences within the pancreatic duct that upsets pancreatic duct homeostasis, initiated by bile toxicity, which starts a chain of events that make up tumor formation, tumor growth and metastasis.
  • Vitalgenics Inc, is seeking capital to enter a phase 1/2 clinical trial and FDA submissions for advanced stage pancreatic cancer.

Xalud Therapeutics Completes Oversubscribed $30 Million Series C Financing

Tuesday, August 24, 2021 - 1:00pm

Xalud Therapeutics, a clinical-stage biotechnology company developing novel non-viral gene therapies to treat pathologic inflammation, announced today that it has raised $30 million in a Series C financing.

Key Points: 
  • Xalud Therapeutics, a clinical-stage biotechnology company developing novel non-viral gene therapies to treat pathologic inflammation, announced today that it has raised $30 million in a Series C financing.
  • We are well positioned to continue advancing XT-150, our lead therapeutic candidate, through clinical development and further expand our platform, said Diem Nguyen, Ph.D., chief executive officer of Xalud Therapeutics.
  • There are over 300 million people worldwide that are impacted by chronic inflammation, a core driver of numerous disease etiologies.
  • Xalud Therapeutics is a biotechnology company developing a non-viral gene therapy platform to treat pathologic inflammation through immune modulation.

Interleukin Inhibitors Global Markets Report 2020-2030: Focus on IL-17, IL-23, IL-1, IL-5, IL-6 - ResearchAndMarkets.com

Thursday, August 19, 2021 - 1:56pm

The "Interleukin Inhibitors Global Market Report 2020-30: COVID-19 Growth and Change" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Interleukin Inhibitors Global Market Report 2020-30: COVID-19 Growth and Change" report has been added to ResearchAndMarkets.com's offering.
  • Major players in the interleukin inhibitors market are Sanofi, GlaxoSmithKline, Novartis, Johnson & Johnson, Roche, Eli Lilly, AstraZeneca, Teva Pharmaceutical and Regeneron Pharmaceuticals.
  • The interleukin inhibitors market consists of the sales of interleukin inhibitors such as interleukin -1, interleukin -5, interleukin -6, interleukin -17, interleukin 23, by companies that manufacture them.
  • Major companies in the interleukins sector are focusing on developing biosimilars for interleukin inhibitors.

Hua Medicine Announces 2020 Interim Results

Thursday, August 19, 2021 - 9:31am

SHANGHAI, CHINA, Aug 19, 2021 - (ACN Newswire) - Hua Medicine (the "Company", Stock Code: 2552.HK), today announces the consolidated results of the Company and its subsidiaries for the six months ended June 30, 2021 (the "Reporting Period").

Key Points: 
  • SHANGHAI, CHINA, Aug 19, 2021 - (ACN Newswire) - Hua Medicine (the "Company", Stock Code: 2552.HK), today announces the consolidated results of the Company and its subsidiaries for the six months ended June 30, 2021 (the "Reporting Period").
  • In the first half of 2021, Hua Medicine reached a breakthrough milestone in preparing for dorzagliatin's commercialization.
  • In anticipation of dorzagliatin commercialization, subject to approval of its NDA, in addition to its CMO partnerships, Hua Medicine has also established Hua Medicine drug manufacture company at Shanghai Lingang Special Area for ensuring adequate dorzagliatin commercial supply.
  • This article contains the statements regarding the future expectation, plan and prospects for Hua Medicine and the investigational product.

Cytocom, Inc. Reports Second Quarter 2021 Financial Results

Monday, August 16, 2021 - 12:30pm

Following the completion of the merger on July 27, 2021, Cytocom, Inc. emerged as a publicly traded entity.

Key Points: 
  • Following the completion of the merger on July 27, 2021, Cytocom, Inc. emerged as a publicly traded entity.
  • The Company did not generate revenue during the second quarter of 2021, compared to $0.06 million in revenue for the second quarter of 2020.
  • Research and development costs for the second quarter of 2021 decreased to $0.05 million compared to $0.17 million for the second quarter of 2020.
  • General and administrative costs for the second quarter of 2021 increased to $0.6 million compared to $0.5 million for the second quarter of 2020.

Cytocom, Inc. and La Jolla Institute for Immunology Announce Five-Year Research Alliance Agreement

Thursday, August 12, 2021 - 9:05pm

Working with the La Jolla Institute, we will deeply explore the mechanisms that we believe will drive next-generation therapeutic development with our AIMS technology and bring hope to patients and their families battling serious medical conditions."

Key Points: 
  • Working with the La Jolla Institute, we will deeply explore the mechanisms that we believe will drive next-generation therapeutic development with our AIMS technology and bring hope to patients and their families battling serious medical conditions."
  • Under the terms of the research agreement, the La Jolla Institute may select up to four laboratories to participate in research.
  • Cytocom will also provide researchers at the La Jolla Institute with samples and materials.
  • Founded in 1988, La Jolla Institute for Immunology is a nonprofit, independent biomedical research institute focused on improving human health through increased understanding of the immune system.